Ind-Swift Limited (INDSWFTLTD.BO)
INR 13.32
(0.53%)
INR 13.32
(0.53%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 640.91 Million INR | -28.27% |
| 2022 | 893.48 Million INR | 28.41% |
| 2021 | 695.82 Million INR | 10.72% |
| 2020 | 628.46 Million INR | 19.92% |
| 2019 | 524.05 Million INR | 6.96% |
| 2018 | 489.95 Million INR | 7.83% |
| 2017 | 454.37 Million INR | 16.33% |
| 2016 | 390.59 Million INR | -57.05% |
| 2015 | 909.4 Million INR | -19.78% |
| 2014 | 1.13 Billion INR | -55.25% |
| 2013 | 2.53 Billion INR | -23.1% |
| 2012 | 3.29 Billion INR | -9.87% |
| 2011 | 3.65 Billion INR | -22.51% |
| 2010 | 4.71 Billion INR | 27.85% |
| 2009 | 3.68 Billion INR | 31.33% |
| 2008 | 2.8 Billion INR | 26.67% |
| 2007 | 2.21 Billion INR | 29.28% |
| 2006 | 1.71 Billion INR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 Q4 | 640.91 Million INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 FY | 640.91 Million INR | -28.27% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 593.46 Million INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q2 | 689.3 Million INR | 0.0% |
| 2022 Q4 | 893.48 Million INR | 0.0% |
| 2022 FY | 893.48 Million INR | 28.41% |
| 2022 Q1 | - INR | -100.0% |
| 2021 FY | 695.82 Million INR | 10.72% |
| 2021 Q4 | 695.82 Million INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 698.33 Million INR | 0.0% |
| 2020 Q2 | 664.64 Million INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 628.46 Million INR | 19.92% |
| 2020 Q4 | 628.46 Million INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 FY | 524.05 Million INR | 6.96% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 548.58 Million INR | 0.0% |
| 2019 Q4 | 524.05 Million INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 489.95 Million INR | 7.83% |
| 2018 Q4 | 489.95 Million INR | 0.0% |
| 2017 Q4 | 454.37 Million INR | 0.0% |
| 2017 FY | 454.37 Million INR | 16.33% |
| 2016 Q4 | 390.59 Million INR | 0.0% |
| 2016 FY | 390.59 Million INR | -57.05% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q2 | 747.64 Million INR | 0.0% |
| 2016 Q3 | - INR | -100.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q4 | 909.4 Million INR | 0.0% |
| 2015 Q2 | 1.07 Billion INR | 0.0% |
| 2015 FY | 909.4 Million INR | -19.78% |
| 2015 Q1 | - INR | -100.0% |
| 2014 Q1 | - INR | -100.0% |
| 2014 Q4 | 1.13 Billion INR | 0.0% |
| 2014 Q3 | - INR | -100.0% |
| 2014 FY | 1.13 Billion INR | -55.25% |
| 2014 Q2 | 1.46 Billion INR | 0.0% |
| 2013 Q4 | 2.53 Billion INR | 0.0% |
| 2013 FY | 2.53 Billion INR | -23.1% |
| 2013 Q3 | - INR | -100.0% |
| 2013 Q2 | 2.41 Billion INR | 0.0% |
| 2013 Q1 | - INR | -100.0% |
| 2012 Q3 | 6.5 Billion INR | 0.0% |
| 2012 Q4 | 3.29 Billion INR | -49.32% |
| 2012 FY | 3.29 Billion INR | -9.87% |
| 2011 FY | 3.65 Billion INR | -22.51% |
| 2010 FY | 4.71 Billion INR | 27.85% |
| 2009 FY | 3.68 Billion INR | 31.33% |
| 2008 FY | 2.8 Billion INR | 26.67% |
| 2007 FY | 2.21 Billion INR | 29.28% |
| 2006 FY | 1.71 Billion INR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.43 Billion INR | 96.1% |
| Aurobindo Pharma Limited | 98.08 Billion INR | 99.347% |
| Glenmark Life Sciences Limited | 6.66 Billion INR | 90.385% |
| Granules India Limited | 13 Billion INR | 95.072% |
| Indoco Remedies Limited | 3.53 Billion INR | 81.847% |
| Achyut Healthcare Limited | 568 Thousand INR | -112737.148% |
| Ajanta Pharma Limited | 8.28 Billion INR | 92.263% |
| Alkem Laboratories Limited | 26.61 Billion INR | 97.592% |
| Alpa Laboratories Limited | 136.65 Million INR | -369.009% |
| Brooks Laboratories Limited | 96.1 Million INR | -566.87% |
| AstraZeneca Pharma India Limited | 2.27 Billion INR | 71.875% |
| Bajaj HealthCare Limited | 1.44 Billion INR | 55.504% |
| Bliss GVS Pharma Limited | 1.18 Billion INR | 45.89% |
| Dr. Reddy's Laboratories Limited | 63.55 Billion INR | 98.992% |
| Eris Lifesciences Limited | 1.89 Billion INR | 66.095% |
| FDC Limited | 3.88 Billion INR | 83.519% |
| Glenmark Pharmaceuticals Limited | 25.13 Billion INR | 97.45% |
| Gufic Biosciences Limited | 2 Billion INR | 68.031% |
| Ind-Swift Laboratories Limited | 104.57 Million INR | -512.864% |
| Ipca Laboratories Limited | 24.71 Billion INR | 97.407% |
| Jagsonpal Pharmaceuticals Limited | 149.97 Million INR | -327.362% |
| Krebs Biochemicals & Industries Limited | 97.96 Million INR | -554.235% |
| Lasa Supergenerics Limited | 190.43 Million INR | -236.555% |
| Laurus Labs Limited | 18.45 Billion INR | 96.527% |
| Lupin Limited | 49.53 Billion INR | 98.706% |
| Mankind Pharma Limited | 15.53 Billion INR | 95.874% |
| Medicamen Biotech Limited | 593.75 Million INR | -7.943% |
| Medico Remedies Limited | 163.37 Million INR | -292.304% |
| Megasoft Limited | - INR | -Infinity% |
| NATCO Pharma Limited | 7 Billion INR | 90.851% |
| Piramal Pharma Limited | 21.75 Billion INR | 97.054% |
| RPG Life Sciences Limited | 1.01 Billion INR | 36.543% |
| Sigachi Industries Limited | 707.2 Million INR | 9.374% |
| Sun Pharmaceutical Industries Limited | 98.68 Billion INR | 99.351% |
| Suven Pharmaceuticals Limited | 2.31 Billion INR | 72.278% |
| Syncom Formulations (India) Limited | 210.81 Million INR | -204.018% |
| Unichem Laboratories Limited | 7.04 Billion INR | 90.905% |
| Wanbury Limited | 360.23 Million INR | -77.917% |
| Windlas Biotech Limited | 621.89 Million INR | -3.059% |
| ZIM Laboratories Limited | 812.62 Million INR | 21.131% |
| Zydus Lifesciences Limited | 34.41 Billion INR | 98.138% |
| Sun Pharma Advanced Research Company Limited | - INR | -Infinity% |
| Divi's Laboratories Limited | 31.84 Billion INR | 97.987% |
| Hester Biosciences Limited | 755.81 Million INR | 15.202% |
| Procter & Gamble Health Limited | 1.09 Billion INR | 41.26% |
| Amrutanjan Health Care Limited | 289.04 Million INR | -121.734% |
| Bal Pharma Limited | 878.11 Million INR | 27.012% |
| Strides Pharma Science Limited | 11.26 Billion INR | 94.309% |
| Venus Remedies Limited | 1.21 Billion INR | 47.332% |
| Aarti Pharmalabs Limited | 6.42 Billion INR | 90.03% |
| Nectar Lifesciences Limited | 7.09 Billion INR | 90.962% |
| Shilpa Medicare Limited | 3.44 Billion INR | 81.419% |
| Aarti Drugs Limited | 4.85 Billion INR | 86.809% |
| IOL Chemicals and Pharmaceuticals Limited | 4.24 Billion INR | 84.914% |
| Suven Life Sciences Limited | 7.08 Million INR | -8946.083% |
| Valiant Laboratories Limited | 100.15 Million INR | -539.93% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.02 Billion INR | 87.246% |
| Solara Active Pharma Sciences Limited | 3.59 Billion INR | 82.182% |
| Themis Medicare Limited | 705.74 Million INR | 9.186% |
| Hikal Limited | 3.03 Billion INR | 78.898% |
| Torrent Pharmaceuticals Limited | 22.79 Billion INR | 97.188% |
| Sequent Scientific Limited | 3.46 Billion INR | 81.489% |
| Novartis India Limited | 448.6 Million INR | -42.87% |
| Wockhardt Limited | 6.4 Billion INR | 89.986% |
| Jubilant Pharmova Limited | 12.89 Billion INR | 95.03% |
| Biofil Chemicals and Pharmaceuticals Limited | 25.49 Million INR | -2413.688% |
| Neuland Laboratories Limited | 3.5 Billion INR | 81.71% |
| Morepen Laboratories Limited | 2.48 Billion INR | 74.218% |
| Kilitch Drugs (India) Limited | 39.88 Million INR | -1507.109% |
| Mangalam Drugs & Organics Limited | 1.23 Billion INR | 48.163% |